MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Dimension Therapeutics Company Profile (NASDAQ:DMTX)

Consensus Ratings for Dimension Therapeutics (NASDAQ:DMTX) (?)
Ratings Breakdown: 2 Hold Rating(s), 6 Buy Rating(s)
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $19.00 (200.63% upside)

Analysts' Ratings History for Dimension Therapeutics (NASDAQ:DMTX)
Show:
DateFirmActionRatingPrice TargetActions
6/22/2016Cantor FitzgeraldReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2016Jefferies GroupInitiated CoverageBuy$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/14/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/30/2016Goldman SachsDowngradeBuy -> Neutral$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/29/2016Chardan CapitalReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/29/2016Citigroup Inc.Lower Price TargetBuy$18.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/3/2015Wells FargoInitiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/6/2015Roth CapitalInitiated CoverageBuy$31.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for Dimension Therapeutics (NASDAQ:DMTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/12/2016        
5/12/2016Q116($0.57)($0.38)$2.24 million$2.21 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/24/2016($0.38)($0.45)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Dimension Therapeutics (NASDAQ:DMTX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.43)($0.43)($0.43)
Q3 20161($0.48)($0.48)($0.48)
Q4 20161($0.53)($0.53)($0.53)
(Data provided by Zacks Investment Research)
Dividend History for Dimension Therapeutics (NASDAQ:DMTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Dimension Therapeutics (NASDAQ:DMTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/7/2016K. Reed ClarkSVPSell5,000$10.00$50,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/27/2015Rishi GuptaDirectorBuy200,000$13.00$2,600,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Dimension Therapeutics (NASDAQ:DMTX)
DateHeadline
06/29/16 07:21 AMDimension Therapeutics to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference - [at noodls] - CAMBRIDGE, Mass., June 29, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, ...
06/24/16 03:46 PMNew Broker Ratings For Argos Therapeutics Inc (ARGS)
06/23/16 07:28 AMNYMX Grabs Headlines, MRNS Awaits Data In 2H, PSTI Takes Small Step In DMD Race
06/22/16 08:20 AMDimension Therapeutics (DMTX) Announces Approval of Phase 1/2 Study Protocol for DTX301
06/22/16 07:09 AMDimension Therapeutics Announces Recombinant DNA Advisory Committee’s Unanimous Approval of Phase 1/2 Study Protocol for DTX301, Lead Inherited Metabolic Disease (IMD) Product Candidate to Treat OTC Deficiency - [at noodls] - CAMBRIDGE, Mass., June 22, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, ...
06/21/16 07:39 AMDimension Therapeutics Opens New Facility in Woburn and Expands Management Team - [at noodls] - CAMBRIDGE, Mass., June 21, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, ...
06/14/16 07:13 AMWill Dimension Therapeutics (DMTX) Continue to Surge Higher? -
06/08/16 07:48 AMIncreased Earnings Estimates Seen for Dimension Therapeutics (DMTX): Can It Move Higher? -
06/08/16 07:06 AMDimension Therapeutics (DMTX) Jumps: Stock Moves 6.7% Up -
06/03/16 03:49 PMCantor Fitzgerald Initiates Dimension At Buy: 'Best In Class Therapies'
06/01/16 12:41 PMDimension Therapeutics, Inc. :DMTX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 -
05/24/16 10:12 AMStocks Gapping Up, May 24 – IDSA, STAF, MSON, DMTX, SSI, FMSA, REXI - The company traded at $4.55 + 0.19 (4.36 pct). Dimension Therapeutics Inc (DMTX) had a gap up of 0.60 pts or 8.34 pct above its previous close of $7.19. The company traded at $7.45 + 0.26 (3.62 pct). Stage Stores Inc. (SSI) had a gap up of (0.2389 ...
05/20/16 03:34 PMDIMENSION THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/19/16 07:32 AMDimension Therapeutics Announces Presentations at the Upcoming 21st Congress of the European Hematology Association (EHA) - [at noodls] - CAMBRIDGE, Mass., May 19, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, ...
05/17/16 10:23 AMAnalysts See 11% Gains Ahead For IWV - SAGE), and Dimension Therapeutics Inc (NASD: DMTX). Although PTCT has traded at a recent price of $7.22/share, the average analyst target is 177.01% higher at $20.00/share. Similarly, SAGE has 153.56% upside from the recent share price of $32.79 if the ...
05/12/16 10:53 AMDimension Therapeutics reports 1Q loss -
05/12/16 08:02 AMDIMENSION THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements -
05/12/16 08:00 AMDimension Therapeutics Reports Recent Corporate Progress and First Quarter 2016 Financial Results - [GlobeNewswire] - Expanded inherited metabolic disease portfolio; New programs address citrullinemia type 1, phenylketonuria, and Wilson disease. Expect to file INDs for lead IMD product candidates, DTX301 for OTC deficiency ...
05/08/16 09:34 AMIn Vivo Preclinical Studies Support a Promising Profile for Lead Candidate Currently in IND-Enabling Studies - CAMBRIDGE, Mass., May 07, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a central organ for devastating rare diseases ...
05/07/16 11:07 AMDimension Therapeutics Announces Preclinical Data from Bayer-Partnered Hemophilia A Program at American Society for Gene and Cell Therapy (ASGCT) Annual Meeting - [at noodls] - CAMBRIDGE, Mass., May 07, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, ...
05/06/16 10:22 AMDimension Therapeutics (DMTX) Announces Research Collaboration With PENN, Expansion of Inherited Metabolic Disease Portfolio - Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here. Dimension Therapeutics, Inc. (NASDAQ: DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a central organ ...
05/05/16 01:31 PMDimension Therapeutics Announces Gene Therapy Research Collaboration with the University of Pennsylvania and Expansion of Inherited Metabolic Disease Portfolio - [at noodls] - Therapeutic Programs Address Citrullinemia Type 1, Phenylketonuria, and Wilson Disease Diseases Can Have Devastating Consequences for Patients and Families, with Few Effective Treatment Options Research ...
05/05/16 07:21 AMDimension Therapeutics Announces Preclinical Data Supporting Ongoing DTX101 Phase 1/2 Clinical Trial at American Society for Gene and Cell Therapy (ASGCT) Annual Meeting - [at noodls] - Findings Demonstrated Dose-Dependent Durable Gene Expression, and No Apparent Safety Issues Across the Dose Range Tested Topline Data from First Cohort in Phase 1/2 Trial of DTX101 Expected in the Second ...
04/28/16 07:19 AMDimension Therapeutics Announces Participation in Two Upcoming Conferences - [at noodls] - CAMBRIDGE, Mass., April 28, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, ...
04/21/16 09:50 AMDimension Therapeutics Incorporated (NASDAQ:DMTX) Shorted Shares Increased By 4.44% - The stock increased 0.24% or $0.02 during the last trading session, hitting $8.36. Dimension Therapeutics Inc (NASDAQ:DMTX) has risen 6.00% since March 22, 2016 and is uptrending. It has underperformed by 0.28% the S&P500. Dimension Therapeutics ...
04/18/16 07:21 AMDimension Therapeutics Announces Presentations at the Upcoming American Society for Gene and Cell Therapy (ASGCT) Annual Meeting - [at noodls] - CAMBRIDGE, Mass., April 18, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, ...
04/13/16 09:49 AMStock Gaps Up Morning Update – ABIL, GLDC, DMTX, CADC, WPRT, BAS, TCK, LEI, CHK, - The company traded at $5.60 + 0.42 (8.11 percent). Dimension Therapeutics Inc (DMTX) posted a gap up of (0.094) pts or -1.43 percent above its previous close of $6.56. The company < traded at $7.10 + 0.54 (8.23 percent). China Advanced Construction ...
04/06/16 07:20 AMDimension Therapeutics to Present at the British Society for Gene and Cell Therapy (BSGCT) Annual Conference - [at noodls] - CAMBRIDGE, Mass., April 06, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, ...
04/01/16 09:26 AMChardan Capital Reiterates a Hold Rating on Dimension Therapeutics Inc - In the prior 12 months Dimension Therapeutics's stock price has increased by 0% from 0.00 to 8.2. Dimension Therapeutics Inc (NASDAQ:DMTX) has risen 6.00% since February 29, 2016 and is uptrending. Dimension Therapeutics, Inc.is based in Cambridge ...
04/01/16 09:26 AMAnalysts Downgrades Report: Dimension Therapeutics Inc - Edge Therapeutics Inc makes up approximately 16.69% of New Leaf Venture Partners L.l.c.'s portfolio. Dimension Therapeutics Inc (NASDAQ:DMTX)'s stock had its "hold" rating reissued by equities research analysts at Chardan Capital in a research note issued ...
04/01/16 09:26 AMDimension Therapeutics Cut to Neutral at Goldman Sachs (NASDAQ:DMTX) - Dimension Therapeutics Inc makes up approx 0.08% of Driehaus Capital Management's portfolio. Dimension Therapeutics (NASDAQ:DMTX), a gene therapy company, on Wednesday was downgraded to neutral from a buy rating at Goldman Sachs. Other Hedge Funds ...
04/01/16 09:26 AMDimension Therapeutics Inc (DMTX) Stock Rating Reaffirmed by Chardan Capital - The research firm set a price target of $10, representing a 22% upside from the stock's previous close. The Company is conducting pre-clinical development activities for its program in hemophilia A. The Company also has access to NAV vector technology in a ...
03/30/16 09:04 AMGoldman On Biotech: Buy Sage, Sell Acorda, Neutral On Dimension - Goldman Sachs downgraded the rating for Dimension Therapeutics Inc (NASDAQ: DMTX) from Buy to Neutral, while reducing the price target from $12 to $10. There is “better near-term opportunities elsewhere in our coverage,” Richter commented. Dimension is ...
03/29/16 12:04 PMDIMENSION THERAPEUTICS, INC. Financials -
03/27/16 08:53 AMPeek Under The Hood: IUSG Has 13% Upside - ... upside to their analyst target prices are Concert Pharmaceuticals Inc (CNCE), Senomyx Inc (SNMX), and Dimension Therapeutics Inc (DMTX). Although CNCE has traded at a recent price of $12.95/share, the average analyst target is 123.94% higher at $29.00 ...
03/25/16 09:10 AMDimension Therapeutics Inc Dips on Earnings Despite Top-Line Strength - worse than what the Street had forecasted Dimension Therapeutics Inc. (NASDAQ:DMTX) shares dipped today, after the company reported earnings results for fourth quarter of fiscal 2015 (4QFY15) and fiscal year 2015 (FY15). DMTX stock went as low as 12.83% ...
03/24/16 08:33 AMDimension Therapeutics Reports Recent Corporate Progress and Full Year 2015 Financial Results - [at noodls] - - Treated first patients in phase I/II clinical study of DTX101 for hemophilia B - - Expect to file an IND and initiate dosing for DTX301 for OTC deficiency in second half 2016 - - Selected candidate for ...
03/24/16 08:30 AMDIMENSION THERAPEUTICS, INC. Files SEC form 10-K, Annual Report -
03/18/16 08:35 AMDimension Therapeutics' (DMTX) DTX301 Receives Positive EMA COMP Opinion as OTC Deficiency Treatment - Dimension Therapeutics, Inc. (Nasdaq: DMTX) announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending DTX301 for designation as an orphan medicinal product for the treatment ...
03/17/16 07:01 AM8:01 am Dimension Therapeutics announces that the EMA has issued a positive opinion recommending DTX301 for designation as an orphan medicinal product for the treatment of Ornithine Transcarbamylase Deficiency -
03/17/16 07:00 AMDimension Therapeutics Receives Positive Opinion for European Orphan Drug Designation for DTX301 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency - [GlobeNewswire] - CAMBRIDGE, Mass., March 17, 2016-- Dimension Therapeutics, Inc., a biopharmaceutical company advancing novel, liver-directed treatments for diverse rare diseases based on an adeno-associated virus gene ...
03/01/16 07:00 AMDimension Therapeutics to Present at Two Upcoming Investor Conferences - [GlobeNewswire] - CAMBRIDGE, Mass., March 01, 2016-- Dimension Therapeutics, Inc., a biopharmaceutical company advancing novel, liver-directed treatments for diverse rare diseases based on an adeno-associated virus gene ...
02/18/16 06:21 AMCoverage initiated on Dimension Therapeutics by Cantor Fitzgerald -
02/14/16 04:46 PMDimension Therapeutics, Inc. (DMTX) - Dimension Therapeutics, Inc., a gene therapy platform company, focuses on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. The company's pipeline of programs ...
02/12/16 06:31 AMDIMENSION THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and -
01/27/16 07:26 AMDimension Therapeutics to Participate in Canaccord Genuity 2016 Rare Disease Biopharma Day and SunTrust Robinson Humphrey 2016 Orphan Drug Day - [at noodls] - , (GLOBE NEWSWIRE) -- (NASDAQ:DMTX), a leading gene therapy company advancing novel, liver-directed treatments for diverse rare diseases, today announced that Dimension's Chief Executive Officer , MBBS, ...
12/14/15 06:55 AMToday's Market Driven by Key Factors - Free Research on Koppers Holdings, Dimension Therapeutics, Fluidigm and Orasure Technologies - [Accesswire] - NEW YORK, NY / ACCESSWIRE / December 14, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Koppers Holdings ...
11/06/15 01:07 PMVoyager plans IPO liftoff next week amid uncertain market -
11/04/15 10:40 AM​With Spark moving in, the Bay State is becoming the world’s gene therapy hub -
11/03/15 03:59 PMDIMENSION THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure -
About Dimension Therapeutics

Dimension Therapeutics logoDimension Therapeutics, Inc. is a United States-based gene therapy company focused on developing novel treatments for rare diseases. The Company is focused on developing treatments for hemophilia A, hemophilia B and rare genetic diseases. The Company's adeno-associated virus (AAV) vector technology enables for systemic administration of the gene therapy in vivo for the treatment of an array of single-gene rare diseases. The Company is conducting pre-clinical development activities for its program in hemophilia A. The Company also has access to NAV vector technology in a range of rare disease indications.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: DMTX
  • CUSIP:
Key Metrics:
  • Previous Close: $6.32
  • 50 Day Moving Average: $7.76
  • 200 Day Moving Average: $8.10
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $158.14M
  • Current Quarter EPS Consensus Estimate: $-1.96 EPS
Additional Links:
Dimension Therapeutics (NASDAQ:DMTX) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha